挪威儿童肺炎球菌疫苗接种变化期间侵袭性肺炎球菌病的抗菌药物敏感性与克隆性
该研究分析了挪威2004-2016年儿童肺炎球菌结合疫苗(PCV)接种计划变化期间10239株侵袭性肺炎球菌病(IPD)分离株的血清型、抗菌药物敏感性及2473株的多位点序列分型。结果显示总体抗菌药物耐药(AMR)率低(最高7%),PCV7期红霉素和复方磺胺甲噁唑耐药IPD减少,但PCV13期出现非疫苗血清型相关的不敏感增加,耐药菌株多为研究期间引入的克隆。携带研究结果与IPD变化相似(每项研究最多9%携带耐药菌)。
要点
- 挪威IPD总体AMR低,最高7%分离株对某抗菌药物耐药。
- PCV7期红霉素和复方磺胺甲噁唑耐药IPD减少,PCV13期非敏感增加。
- PCV13期增加主要由非疫苗血清型15A-ST63等多药耐药克隆驱动。
核心结论
- 挪威2004-2016年IPD总体AMR低,但PCV13期出现非疫苗血清型相关的不敏感增加,耐药菌株多为引入克隆。
研究设计与样本
- 研究纳入挪威2004-2016年10239株IPD分离株,并对2473株系统收集的分离株进行多位点序列分型。
- 补充2006、2008、2013和2015年日托儿童携带研究分离株。
- IPD病例来自挪威全国人口,年龄0-102岁(中位64岁);携带研究参与者通常1-5岁。
主要发现
- 总体AMR低,最多7%的IPD分离株对某抗菌药物耐药。
- PCV7期(2006-2010)红霉素耐药(ERY-R)和复方磺胺甲噁唑耐药(SXT-R)IPD减少。
- PCV13期(2011-2016)出现IPD分离株非敏感增加的迹象,主要涉及非疫苗血清型15A-ST63(多药耐药)、24F-ST162(SXT-R)、23B-ST2372(青霉素不敏感和SXT-R)和33F(ERY-R和克林霉素耐药)。
- 耐药或不敏感IPD分离株常为研究期间引入挪威的克隆;例外是ERY-R分离株,初期主要为已建立的血清型14-ST9克隆,引入PCV7后消失。
- 携带研究结果与IPD变化相似,每项研究中最多9%的参与者携带耐药肺炎球菌。
临床怎么用
- 当前PCV不能完全限制AMR,仍需更高价疫苗和审慎使用抗菌药物以遏制肺炎球菌AMR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Changes in pneumococcal antimicrobial resistance (AMR) have been reported following use of pneumococcal conjugate vaccines (PCVs) in childhood vaccination programmes. We describe AMR trends and clonality in Norway during 2004-2016; we studied 10,239 invasive pneumococcal disease (IPD) isolates in terms of serotypes, antimicrobial susceptibility, and for a systematically collected subset of 2473 isolates, multilocus sequence types (ST). The IPD cases were notified to the Norwegian Surveillance System for Communicable Diseases and pneumococcal isolates were collected through the National Reference Laboratory for Pneumococci. The cases are sourced from the entire Norwegian population. We supplemented the IPD isolates with isolates from carriage studies in children attending day-care, performed in 2006 (before mass childhood vaccination with PCV7), 2008 (2 years after PCV7 introduction), 2013 (2 years after the transition to PCV13), and 2015. IPD cases were 0-102 years old; median 64 years. Carriage study participants were typically aged 1-5 years. Overall, AMR was low; a maximum of 7% of IPD isolates were resistant, depending on the antimicrobial. Erythromycin and trimethoprim/sulfamethoxazole resistant IPD (ERY-R and SXT-R, respectively) decreased in the PCV7 period (2006-2010). In the PCV13 period (2011-2016) however, we saw an indication of increased non-susceptibility among IPD isolates. This increase was mainly due to non-vaccine serotypes 15A-ST63 (multidrug resistant), 24F-ST162 (SXT-R), 23B-ST2372 (penicillin non-susceptible and SXT-R) and 33F (ERY-R and clindamycin resistant). Resistant or non-susceptible IPD isolates were often clones introduced into Norway during the study period. The exception was ERY-R isolates; initially, these largely consisted of an established serotype 14-ST9 clone, which disappeared after introducing PCV7. The carriage study results mostly resembled the changes seen in IPD with a maximum of 9% of the participants per study carrying resistant pneumococci. As actual PCVs are not fully limiting AMR, higher-valency vaccines and prudent use of antimicrobials are still needed to temper pneumococcal AMR.
引用
- Siira L, Vestrheim DF, Winje BA, et al. Antimicrobial susceptibility and clonality of Streptococcus pneumoniae isolates recovered from invasive disease cases during a period with changes in pneumococcal childhood vaccination, Norway, 2004-2016. Vaccine. 2020. PMID: 32616324. doi:10.1016/j.vaccine.2020.06.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。